砷剂一线治疗后复发急性早幼粒细胞白血病的管理
该研究评估了67例接受含砷剂(ATO)一线方案后复发、并再次使用含砷剂方案挽救治疗的急性早幼粒细胞白血病(APL)患者。挽救治疗后94%患者获得第二次分子学缓解,接受自体干细胞移植(auto-SCT)者5年总生存率和无事件生存率显著优于未移植者。多因素分析显示未以auto-SCT巩固分子学缓解与复发风险显著增加相关。
要点
- 含砷剂方案再诱导可使94%复发APL患者获得第二次分子学缓解
- 获得分子学缓解后行auto-SCT者5年OS和EFS显著优于未移植者
- 未以auto-SCT巩固分子学缓解与复发风险显著增加独立相关
核心结论
- 含砷剂方案诱导分子学缓解后行auto-SCT,在经含砷剂一线治疗的儿童和年轻复发APL患者中与优异的长期生存相关。
研究设计与样本
- 回顾性评估67例接受含砷剂一线方案后复发、并再次使用含砷剂方案挽救治疗的APL患者,中位年龄28岁(范围4-54岁)。
临床怎么用
- 对于含砷剂一线治疗后复发的APL患者,可考虑含砷剂方案再诱导,获得分子学缓解后行auto-SCT巩固。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard of care for patients with acute promyelocytic leukaemia (APL) relapsing after front-line treatment with arsenic trioxide (ATO)-based regimens remains to be defined. A total of 67 patients who relapsed after receiving ATO-based up-front therapy and were also salvaged using an ATO-based regimen were evaluated. The median (range) age of patients was 28 (4-54) years. While 63/67 (94%) achieved a second molecular remission (MR) after salvage therapy, three (4·5%) died during salvage therapy. An autologous stem cell transplant (auto-SCT) was offered to all patients who achieved MR, 35/63 (55·6%) opted for auto-SCT the rest were administered an ATO + all-trans retinoic acid maintenance regimen. The mean (SD) 5-year Kaplan-Meier estimate of overall survival and event-free survival of those who received auto-SCT versus those who did not was 90·3 (5·3)% versus 58·6 (10·4)% (P = 0·004), and 87·1 (6·0)% versus 47·7 (10·3)% (P = 0·001) respectively. On multivariate analysis, failure to consolidate MR with an auto-SCT was associated with a significantly increased risk of relapse [hazard ratio (HR) 4·91, 95% confidence interval (CI) 1·56-15·41; P = 0·006]. MR induction with ATO-based regimens followed by an auto-SCT in children and young adults with relapsed APL who were treated with front-line ATO-based regimens was associated with excellent long-term survival.
引用
- Fouzia NA, Sharma V, Ganesan S, et al. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol. 2020. PMID: 33216980. doi:10.1111/bjh.17221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。